Article
Biochemical Research Methods
Seunghyun Wang, Doheon Lee
Summary: In this study, two prognostic subgroups (BPS-LumA and WPS-LumA) of luminal-A breast cancer were identified using deep autoencoders and gene expressions. The prognostic difference between the two subgroups was validated using external datasets. The study also found that latent features were superior to gene expression profiles in discovering the prognostic subgroups.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Yao Tian, Zhao-Hui Chen, Peng Wu, Di Zhang, Yue Ma, Xiao-Feng Liu, Xin Wang, Dan Ding, Xu-Chen Cao, Yue Yu
Summary: The deficiency of MIR497HG contributes to breast cancer progression and tamoxifen resistance by downregulating miR-497/195. miR-497/195 collectively represses five PI3K-AKT regulators, resulting in inhibition of PI3K-AKT signaling. Additionally, ERα binds to the MIR497HG promoter to activate its transcription in an estrogen-dependent manner. ZEB1 interacts with HDAC1/2 and DNMT3B at the MIR497HG promoter, leading to promoter hypermethylation and histone deacetylation.
Article
Oncology
Noorul Wahab, Michael Toss, Islam M. Miligy, Mostafa Jahanifar, Nehal M. Atallah, Wenqi Lu, Simon Graham, Mohsin Bilal, Abhir Bhalerao, Ayat G. Lashen, Shorouk Makhlouf, Asmaa Y. Ibrahim, David Snead, Fayyaz Minhas, Shan E. Ahmed Raza, Emad Rakha, Nasir Rajpoot
Summary: The study proposes an image-based prognostic marker for breast cancer that uses deep learning to objectively assess tumor heterogeneity. The marker demonstrates the ability to predict both patient survival and distant metastasis in early-stage breast cancer, with comparable accuracy to traditional manual assessment methods.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Chunxiao Sun, Xiang Huang, Jun Li, Ziyi Fu, Yijia Hua, Tianyu Zeng, Yaozhou He, Ningjun Duan, Fan Yang, Yan Liang, Hao Wu, Wei Li, Yuchen Zhang, Yongmei Yin
Summary: This study identified a small ncRNA, tRF-16-K8J7K1B, which is highly expressed in tamoxifen-resistant cells compared to parental cells. Extracellular tRF-16-K8J7K1B confers tamoxifen resistance via incorporation into exosomes and downregulating apoptosis-related proteins. The findings suggest that exosomal tRF-16-K8J7K1B could be a potential biomarker and therapeutic target for overcoming tamoxifen resistance.
Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Oncology
Yuxing Wang, Xiaohua Pan, Yanjun Li, Ru Wang, Yuanyuan Yang, Baichun Jiang, Gongping Sun, Changshun Shao, Molin Wang, Yaoqin Gong
Summary: CUL4B promotes TAM resistance in breast cancer cells by upregulating ER-alpha 36 expression through the regulation of miR-32-5p. This mechanism involves epigenetic modifications mediated by CRL4B, PRC2, and HDAC complexes, and targeting these complexes can increase sensitivity to TAM in breast cancer cells.
JOURNAL OF PATHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mithil Soni, Ozge Saatci, Gourab Gupta, Yogin Patel, Manikanda Raja Keerthi Raja, Jie Li, Xinfeng Liu, Peisheng Xu, Hongjun Wang, Daping Fan, Ozgur Sahin, Hexin Chen
Summary: The study reveals the crucial role of miR-489 in regulating estrogen signaling and tamoxifen resistance in breast cancer. miR-489 negatively regulates estrogen receptor signaling and overexpression of miR-489 can restore tamoxifen sensitivity in resistant cells. Additionally, miR-489 disrupts the positive feed-forward loop in breast cancer cells and functions as a transcription factor.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Katharina Hutter, Thomas Rulicke, Tamas G. Szabo, Lill Andersen, Andreas Villunger, Sebastian Herzog
Summary: MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in the development and function of immune cells. The miR-15 family has been shown to suppress tumors in chronic lymphocytic leukemia. However, its physiological functions are not well understood. This study reveals that the miR-15 family restricts the expansion of progenitor B cells by inhibiting cell cycle regulators and IL-7 receptor expression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hyeon Woo Kim, Minjae Baek, Sanghyun Jung, Siyeon Jang, Hyeonjin Lee, Seung-Hoon Yang, Beom Seok Kwak, Sun Jung Kim
Summary: This study identifies the role of the ELOVL2-AS1/ELOVL2/miR-1233-3p signaling pathway in drug resistance in Tam-resistant breast cancer, suggesting its potential as a target for therapy.
Article
Genetics & Heredity
Yingxia Ying, Yiling Meng, Lei Bian, Meichao Zhang, Pingting Zhou, Suning Zhang, Wei Wang, Yuan Yao, Qing Ren, Dong Li
Summary: This study aims to explore the functions and potential mechanism of HFM1 in breast cancer. Bioinformatic analysis revealed that HFM1 was downregulated in breast cancer with poor prognosis and may modulate DNA damage repair pathways and immune infiltration. Additionally, HFM1 may mediate ovarian steroidogenesis and participate in tamoxifen resistance of estrogen receptor-positive breast cancer cells.
Review
Biochemistry & Molecular Biology
Dada Wen, Huamin Zhang, Yutong Zhou, Jie Wang
Summary: This article reviews the important role and regulatory mechanisms of miR-15a/16 in fibrotic diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Junbiao Liu, Zhijian Dai, Minmin Li, Bicheng Wang, Xiao Zhang, Feng Li, Meng Zhang, Wenqian Zhang
Summary: This study investigated the role of circular RNA circMET in modulating tamoxifen resistance in breast cancer cells, and found that circMET promotes tamoxifen resistance by targeting the miR-204-5p/AHR signaling pathway.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Cell Biology
Yongyi Chen, Jie Zhang, Wangang Gong, Wumin Dai, Xiaohong Xu, Songxiao Xu
Summary: The study identified miR-588 as a potential therapeutic target and prognostic biomarker for gastric cancer. Overexpression of miR-588 inhibited GC cell proliferation, and higher expression correlated with prolonged survival of patients. Additionally, miR-588 was found to regulate CXCL5, CXCL9, and CXCL10, which are involved in immune responses and T cell infiltration in stomach adenocarcinoma.
Article
Oncology
Mohammad Imran Khan, Aamir Ahmad
Summary: The study revealed that lncRNA SNHG6 plays a role in tamoxifen resistance of ER-positive breast cancer cells by modulating EMT through sponging miR-101.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Penn Muluhngwi, Carolyn M. Klinge
Summary: Despite improvements in treating endocrine-resistant metastatic diseases using combination therapies, the mechanisms underlying endocrine resistance are still unclear. Non-coding RNAs, such as miRNA and lncRNA, have been shown to play a role in cell signaling pathways and metastasis. This study identified miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, offering new insights into potential therapeutic targets.
Article
Biochemistry & Molecular Biology
Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong
Summary: The study identified a circRNA circCDYL2 that is overexpressed in HER2(+) breast cancer patients resistant to trastuzumab, playing a critical role in maintaining HER2 signaling and contributing to trastuzumab resistance. High levels of circCDYL2 were associated with rapid recurrence and shorter survival in HER2(+) breast cancer patients, suggesting circCDYL2 as a potential biomarker for trastuzumab resistance.
Meeting Abstract
Oncology
Qiang Liu, Zijie Cai, Jingru Wang, Yudong Li, Lok Lam Wong
Meeting Abstract
Oncology
Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Tao Zhang, Jianjun Zou
Article
Biology
Chang Gong, Ziliang Cheng, Yaping Yang, Jun Shen, Yingying Zhu, Li Ling, Wanyi Lin, Zhigang Yu, Zhihua Li, Weige Tan, Chushan Zheng, Wenbo Zheng, Jiajie Zhong, Xiang Zhang, Yunjie Zeng, Qiang Liu, R. Stephanie Huang, Andrzej L. Komorowski, Eddy S. Yang, Francois Bertucci, Francesco Ricci, Armando Orlandi, Gianluca Franceschini, Kazuaki Takabe, Suzanne Klimberg, Naohiro Ishii, Angela Toss, Mona P. Tan, Mathew A. Cherian, Erwei Song
Summary: This study developed a model based on a 10-microRNA risk score that accurately predicts the pathological complete response to neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. The model was also validated to be associated with disease-free survival.
SCIENCE CHINA-LIFE SCIENCES
(2022)
Article
Multidisciplinary Sciences
Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Yinduo Zeng, Weijuan Jia, Yaping Yang, Shengqiang Xu, Herui Yao, Wen Jiang, Erwei Song
Summary: This multicentered phase II trial evaluated the efficacy and safety of camrelizumab in combination with apatinib and eribulin for heavily pre-treated advanced TNBC patients. The results showed that this combination therapy showed promising efficacy and an acceptable safety profile in this population.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David A. Cameron
Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Xin Zhao, Liang Jin, Yujie Liu, Zhenzhen Liu, Qiang Liu
Summary: This study using bioinformatics analysis found that increased expression levels of SLC-related glutamine transporters were associated with poor prognosis in breast cancer patients, while decreased expression levels of SLC6A14 and SLC38A1 were also associated with poor prognosis. Additionally, these SLC-related proteins may regulate the polarization of tumor-associated macrophages.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Hengming Ye, Lu-Ying Tang, Zhuo-Zhi Liang, Qian-Xin Chen, Yun-Qian Li, Qiang Liu, Xiaoming Xie, Ying Lin, Ze-Fang Ren
Summary: This prospective cohort study investigated the impact of fever and its interaction with IL6 rs1800796 on breast cancer survival. The study found that pre-diagnostic fever and IL6 rs1800796 CC genotype were associated with a reduced risk of disease progression and improved overall survival in breast cancer patients. Post-diagnostic fever also conferred a better progression-free survival. These findings suggest that infection-induced fever may serve as a potential prognostic marker and therapy regimen for breast cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Biology
Zijie Cai, Jingru Wang, Yudong Li, Qianfeng Shi, Liang Jin, Shunying Li, Mengdi Zhu, Qi Wang, Lok Lam Wong, Wang Yang, Hongna Lai, Chang Gong, Yandan Yao, Yujie Liu, Jun Zhang, Herui Yao, Qiang Liu
Summary: CDK4/6 inhibitors are standard treatment for advanced HR+/HER2- breast cancer, but resistance is inevitable. This study found that overexpression of Cyclin D1 and CDK4 proteins leads to resistance, and targeting the PI3K/mTOR pathway can restore sensitivity.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Article
Medicine, General & Internal
Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Xiang Lin, Jianjun Zou
Summary: This study demonstrates that neoadjuvant pyrotinib, trastuzumab, and docetaxel significantly improve the total pathological complete response rate compared to placebo, trastuzumab, and docetaxel in patients with HER2-positive early or locally advanced breast cancer, with manageable toxicity. This provides a new option for the treatment of HER2-positive breast cancer.
Article
Oncology
Binghe Xu, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Jiayu Wang, Min Yan, Xi Yan, Chuan Wang, Jifeng Feng, Xiuli Wang, Gang Hu, Ying Cheng, Ruimin Ge, Zhaoyin Zhu, Wa Zhang, Zhimin Shao
Summary: This study conducted in China showed that Pamiparib had promising efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2-negative breast cancer with deleterious or suspected deleterious gBRCA1/2 mutations.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Xiao-ting Jiang, Qiang Liu
Summary: Messenger RNA (mRNA) vaccination is highly successful against COVID-19 and has sparked tremendous interest. It is also viewed as a promising treatment strategy for cancer immunotherapy. However, breast cancer patients have limited access to immunotherapy benefits. This review discusses the potential of mRNA vaccination to convert cold breast cancer into hot and improve efficacy by combining appropriate vaccination platforms or other immunotherapies.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Zijie Cai, Qianfeng Shi, Yudong Li, Liang Jin, Shunying Li, Lok Lam Wong, Jingru Wang, Xiaoting Jiang, Mengdi Zhu, Jinna Lin, Qi Wang, Wang Yang, Yujie Liu, Jun Zhang, Chang Gong, Herui Yao, Yandan Yao, Qiang Liu
Summary: This study reveals that a long non-coding RNA (EILA) that interacts with cyclin E1 is up-regulated in CDK4/6 inhibitor-resistant breast cancer cells and contributes to resistance by stabilizing cyclin E1 protein. EILA overexpression is associated with accelerated cell cycle progression and poor prognosis in breast cancer. Silencing EILA reduces cyclin E1 protein and restores sensitivity to CDK4/6 inhibitors both in vitro and in vivo.
Article
Biology
Jing Zhou, Mengdi Zhu, Qi Wang, Yiyuan Deng, Nianqiu Liu, Yujie Liu, Qiang Liu
Summary: Endocrine resistance is a major challenge in breast cancer therapy. Through screening five datasets, we identified 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Our study suggests that downregulation of SERPINA3, a direct target gene of estrogen receptor alpha, contributes to aromatase inhibitor resistance. ANKRD11 acts as a downstream effector of SERPINA3 in mediating endocrine resistance by interacting with HDAC3 and upregulating its activity.
COMMUNICATIONS BIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jiafan Ma, Kai Chen, Shunrong Li, Liling Zhu, Yunfang Yu, Jingwu Li, Jie Ma, Jie Ouyang, Zhuo Wu, Yujie Tan, Zifan He, Haiqing Liu, Zhilong Pan, Haojiang Li, Qiang Liu, Erwei Song
Summary: An MRI-based radiomic model was developed to predict the risk of margin positivity in breast-conserving surgery. The model can stratify patients into different risk subgroups and is associated with tumor immune-microenvironment alterations.
EUROPEAN RADIOLOGY
(2023)